Literature DB >> 33440291

D-arginine-loaded metal-organic frameworks nanoparticles sensitize osteosarcoma to radiotherapy.

Chuanchao Du1, Mengxue Zhou2, Fei Jia1, Lifo Ruan2, Huiru Lu2, Jiayu Zhang2, Bin Zhu1, Xiaoguang Liu3, Jun Chen4, Zhifang Chai2, Yi Hu5.   

Abstract

Osteosarcoma is a common type of bone cancers with a high rate of pulmonary recurrence. High-dose radiation therapy is useful for the ablation of unresectable osteosarcoma. However, it may cause severe adverse effects. To address this problem, we developed D-arginine-loaded metal-organic frameworks (MOF) nanoparticles for improving the radiosensitivity of osteosarcoma. D-arginine, a metabolically inert enantiomer of L-arginine, could produce nitric oxide and down-regulate hypoxia-inducible factor-1alpha (HIF-1α) to alleviate tumor hypoxia. In addition, MOF could also generate free radicals to kill the tumor cells. Results demonstrate that D-arginine-loaded nanoparticles enhanced tumor ablation and prevented the lung metastasis in mice upon radiation therapy. Furthermore, the nanoparticles or radiation alone had relatively low toxicity in cells and mice. Therefore, D-arginine-loaded MOF nanoparticles are relatively safe and highly effective in sensitizing osteosarcoma to radiotherapy.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  D-arginine; Hypoxia; Metal-organic frameworks; Osteosarcoma; Radiotherapy

Mesh:

Substances:

Year:  2021        PMID: 33440291     DOI: 10.1016/j.biomaterials.2020.120642

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  10 in total

1.  Epithelial to Mesenchymal Transition Relevant Subtypes with Distinct Prognosis and Responses to Chemo- or Immunotherapies in Osteosarcoma.

Authors:  Yang Zhou; Gai Li; Hu Li; Fuchong Lai; Pingguo Duan; Ming Cheng
Journal:  J Immunol Res       Date:  2022-07-04       Impact factor: 4.493

2.  Graphene Oxide Nanoparticle-Loaded Ginsenoside Rg3 Improves Photodynamic Therapy in Inhibiting Malignant Progression and Stemness of Osteosarcoma.

Authors:  Shou-Liang Lu; Yan-Hua Wang; Guang-Fei Liu; Lu Wang; Yong Li; Zhi-Yuan Guo; Cai Cheng
Journal:  Front Mol Biosci       Date:  2021-04-22

3.  Metal-Organic Frameworks (MOFs) for Cancer Therapy.

Authors:  Mohammad Reza Saeb; Navid Rabiee; Masoud Mozafari; Francis Verpoort; Leonid G Voskressensky; Rafael Luque
Journal:  Materials (Basel)       Date:  2021-11-28       Impact factor: 3.623

4.  Penetration Enhancing of an Erythrocyte-Mimicking Nanoplatform via Papaverine for Radiosensitization.

Authors:  Jinrui Zhang; Huaicheng Wang; Weilong Suo; Zhizhou Li; Chunxu Yang
Journal:  Int J Nanomedicine       Date:  2021-10-12

5.  Hypoxia Alleviating PdTe Nanoenzymes for Thermoradiotherapy.

Authors:  Yang Li; Xinquan Gu; Fan Yu
Journal:  Front Bioeng Biotechnol       Date:  2022-03-11

Review 6.  Application of MOF-based nanotherapeutics in light-mediated cancer diagnosis and therapy.

Authors:  Dan Zhao; Wang Zhang; Shuang Yu; Si-Lei Xia; Ya-Nan Liu; Guan-Jun Yang
Journal:  J Nanobiotechnology       Date:  2022-09-24       Impact factor: 9.429

Review 7.  Current Status and Prospects of Clinical Treatment of Osteosarcoma.

Authors:  Zong-Yuan Jiang; Ji-Bin Liu; Xiao-Feng Wang; Yu-Shui Ma; Da Fu
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

Review 8.  Explaining chemical clues of metal organic framework-nanozyme nano-/micro-motors in targeted treatment of cancers: benchmarks and challenges.

Authors:  Mojtaba Falahati; Majid Sharifi; Timo L M Ten Hagen
Journal:  J Nanobiotechnology       Date:  2022-03-24       Impact factor: 10.435

9.  Liensinine Inhibits Osteosarcoma Growth by ROS-Mediated Suppression of the JAK2/STAT3 Signaling Pathway.

Authors:  Fei Jia; Yu Liu; Xinyu Dou; Chuanchao Du; Tianli Mao; Xiaoguang Liu
Journal:  Oxid Med Cell Longev       Date:  2022-01-25       Impact factor: 6.543

Review 10.  Chemodynamic nanomaterials for cancer theranostics.

Authors:  Jingqi Xin; Caiting Deng; Omer Aras; Mengjiao Zhou; Chunsheng Wu; Feifei An
Journal:  J Nanobiotechnology       Date:  2021-06-28       Impact factor: 10.435

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.